World Journal of Analytical Chemistry
ISSN (Print): 2333-1178 ISSN (Online): 2333-1283 Website: Editor-in-chief: Raluca-Ioana Stefan-van Staden
Open Access
Journal Browser
World Journal of Analytical Chemistry. 2014, 2(2), 23-30
DOI: 10.12691/wjac-2-2-2
Open AccessArticle

Design of Experiment Assisted UV-Visible Spectrophotometric and RP-HPLC Method Development for Ambrisentan Estimation in Bulk and Formulations

Shanta K. Adiki1, Prashanti M1, Baishakhi Dey2, Prakash Katakam3, , Fathi H. Assaleh3, Nagiat T. Hwisa3, Rajeev K. Singla4 and Babu R. Chandu3

1Department of Pharmaceutical Analysis, Nirmala College of Pharmacy, Guntur, India

2School of Medical Science & Technology, Indian Institute of Technology, Kharaghpur, India

3Faculty of Pharmacy, University of Zawia, Az Zawiyah, Libya

4Division of Biotechnology, Netaji Subhas Institute of Technology, New Delhi, India

Pub. Date: June 04, 2014

Cite this paper:
Shanta K. Adiki, Prashanti M, Baishakhi Dey, Prakash Katakam, Fathi H. Assaleh, Nagiat T. Hwisa, Rajeev K. Singla and Babu R. Chandu. Design of Experiment Assisted UV-Visible Spectrophotometric and RP-HPLC Method Development for Ambrisentan Estimation in Bulk and Formulations. World Journal of Analytical Chemistry. 2014; 2(2):23-30. doi: 10.12691/wjac-2-2-2


Design of experiment (DOE) approach reinforces the robustness of the method being developed. This was employed for UV-visible (200-400 nm and 400-800 nm respectively) and RP-HPLC method development using C18 inertsil column and optimization of variables for ambrisentan (ABN) estimation in bulk and formulations. A two-level full factorial design assisted development of a visible spectroscopic method based on the principle of oxidation and coupling reaction of ABN with 3-methyl-2-benzothiazolinone hydrazone (MBTH reagent) in presence of FeCl3 to form bluish-green chromogen which is detectable in the visible range. second method estimates ABN in bulk and tablet dosage forms in the UV range using pH 7.4 phosphate buffer and the third one is a rapid, simple, stability indicating RP-HPLC method using a degassed mixture of orthophosphoric acid (OPA, 0.05M): acetonitrile (40:60) as mobile phase with water: acetonitrile (30:70) as diluent using PDA detector set at 264 nm for routine estimation of ABN in bulk and pharmaceutical dosage forms. Experimental design, data analysis and contour plots were developed using Minitab® 16.2.4 trial version (Minitab Inc). The percent assay of ABN detected by visible spectroscopy was 100.58±101.37% with RSD value 0.38%, by UV spectroscopy it was 99.1±99.8% with 0.5% RSD value and by RP-HPLC it was found 100.9%. The values of method validation parameters of three methodologies were found within the acceptance limits. The three methodologies could be regarded as specific, accurate, precise, with significant stability and robustness for routine estimation of ABN in bulk and tablet dosage forms.

Ambrisentan Antihypertensive Experimental design RP-HPLC Spectrophotometric Validation

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Higuchi, T., Brochmann-Hansen, E, Pharmaceutical Analysis, CBS publications, New Delhi, 1997.
[2]  Douglas, A., Skoog, F., Holler, J, Fundamentals of Analytical Chemistry, Broks/Cole publications, Stamford, 2009.
[3]  Willard, H.H., Merritt, L.L., Dean, J.A., Settle, F.A, Instrumental Methods of Analysis, CBS Publishers, New Delhi, 1986.
[4]  The Merck Index. An encyclopedia of chemicals drugs and biologics. 14th edition, Merck and Co., New Jersey, 2006.
[5]  Martindale. The Complete Drug Reference, 33rd edition, Edited by Sweetman S.C, Pharmaceutical Press, London, 2002.
[6]  Nirogi, R., Kandikere, V., Komarneni, P., Aleti, R., Padala, N, “Kalaikadhiban I: LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study,” Biomedical Chromatography, 26 (10). 1150-1156, Oct. 2012.
[7]  Dousa, M., Gibala, P, “Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode,” Journal of Separation Science, 35 (7), 798-803, Apr. 2012.
[8]  Kumar, N.S., Avula, P.R., Telu, V., Sekaran, C.B, “Extractive spectrophotometric determination of ambrisentan,” Advanced Pharmaceutical Bulletin, 3 (1). 231-237. Feb. 2013.
[9]  Seshamamba, B.S.V., Satyanarayana, P.V.V., Sekaran, C.B, “Spectrophotometric methods for the determination of ambrisentan using charge transfer reagents,” Journal of Applied Chemical Reserach, 7 (3). 7-14. Jul. 2013.
[10]  Prathyusha, V., Siddartha, B., Sowmya, B., Madhavi, C., Kalyani, N, “A validated UV spectrophotometric method for the estimation of ambrisentan in pure and tablet dosage forms,” Inventi Rapid: Pharm Analysis & Quality Assurance 2014. Article ID Inventi: ppaqa/1266/13.
[11]  Nanjappan, S.K., Gandham, N.K, “A stability indicating reversed phase high performance liquid chromatography method for ambrisentan: an endothelin receptor antagonist,” Journal of Chromatographic Science, in press. 2013.
[12]  Narayana, M.B.V., Chandrasekhar, K.B., Rao, B.M, “A validated specific stability indicating RPHPLC assay method for ambrisentan and its related substances,” Journal of Chromatographic Science, in press. 2013.
[13]  Ramalingam, S., Rajappan, M., Valliappan, K, “HPLC method for the simultaneous determination of levocetirizine, ambroxol and montelukast in human plasma employing response surface methodology,” International Journal of Drug Development and Research, 4 (3). 173-185. Jul. 2012.
[14]  Wani, Y.B., Patil, D.D, “An experimental design approach for optimization of spectrophotometric method for estimation of cefixime trihydrate using ninhydrin as derivatizing reagent in bulk and pharmaceutical formulation,” Journal of Saudi Chemical Society, 2013. Online.
[15]  Gohel, N.R., Patel, B.K., Parmar, V.K, “Chemometrics assisted UV spectrophotometric and RP-HPLC methods for the simultaneous determination of tolperisone hydrochloride and diclofenac sodium in their combined pharmaceutical formulation,” Scientia Pharmaceutica, 81 (4), 983-1001. Dec. 2013.
[16]  Vadeya, C.M., Yadav, D.S., Jogia, H.A., Chauhan, P.L, “Design of experiment (DOE) utilization to develop a simple and robust reversed phase HPLC technique for related substances estimation of omeprazole formulations,” Scientia Pharmaceutica, 81 (4), 1043-1056. Dec. 2013.
[17]  Balakrishna, M., Aziz, U., Prabhakar, R., Suma, C.H, “RP-HPLC-PDA method for the analysis of ambrisentan in bulk drugs and pharmaceutical dosage forms,” Int J Chem Pharm Sci, 4 (4), 45-50. Dec. 2013.
[18]  Yanmandru, V.K., Murali, D., Rambabu, C., “New visible spectrophotometric methods for determination of ambrisentan,” Bull. Pharm Res Poster presentation, Proceedings of APP 1st Annual National Convention, 2012.
[19]  Sreenivasulu, J., Nagaraju, C.H.V.S., Rajan, S.T., Eswaraiah, S., Ramana, P.V., “Development and validation of novel stability indicating RP-HPLC method for estimation of related substances and degradation products in Ambrisentan.,” Anal Chem , 14 (1) 2014.
[20]  Nageswara Rao, R., Ramakrishna, K., “LC-MS/MS characterization of forced degradation products of ambrisentan: development and validation of a stability-indicating RP-HPLC method” New J Chem Mar. 2014.
[21]  Yoshinari, Y., Miho, T., Hideki, H., Keita, H., Yasuo, O., Yuto, Y., Kenichiro, T., Toshimasa, T., Hiroshi, Y., Kunihiko, I., “Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension,” J Pharm Biomed Anal, 89, 227-232. Feb. 2014.
[22]  Intenational Conference on Hormonization (ICH) Harmonized Tripartate Guideline. Validation of analytical procedures: Text and Methodology, Q2 (R1). Switzerland: 2005, 1-13.